Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.87USD
15 Dec 2017
Change (% chg)

$-0.08 (-4.10%)
Prev Close
$1.95
Open
$1.95
Day's High
$1.97
Day's Low
$1.84
Volume
3,436,152
Avg. Vol
438,388
52-wk High
$2.87
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab
Wednesday, 29 Nov 2017 07:30am EST 

Nov 29 (Reuters) - Idera Pharmaceuticals Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA.  Full Article

Idera Pharmaceuticals reports Q3 loss per share $0.10
Monday, 6 Nov 2017 04:02pm EST 

Nov 6 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.10.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Idera Pharmaceuticals Inc - ‍ as of September 30, 2017, cash, cash equivalents and investments totaled $65.3 million​.Idera Pharmaceuticals Inc - ‍currently anticipate cash position capable of funding co's operations into Q2 of 2019​.  Full Article

Idera Pharma announces pricing of public offering of common stock
Thursday, 26 Oct 2017 07:00am EDT 

Oct 26 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 33.3 million common shares priced at $1.50 per share.  Full Article

Idera Pharmaceuticals announces proposed public offering of common stock
Tuesday, 24 Oct 2017 04:01pm EDT 

Oct 24 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals announces proposed public offering of common stock.Idera Pharmaceuticals Inc - ‍intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering​.Idera - intends to use net proceeds from offering, together with existing cash to advance development of IMO-2125 in its immuno-oncology program​.  Full Article

Idera Pharmaceuticals Q2 loss per share $0.14
Monday, 7 Aug 2017 05:00pm EDT 

Aug 7 (Reuters) - Idera Pharmaceuticals Inc :Q2 loss per share $0.14.Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Idera Pharmaceuticals Inc - ‍as of June 30, 2017, our cash, cash equivalents and investments totaled $77.2 million​.Idera Pharmaceuticals Inc - ‍currently anticipate our cash position is capable of funding our operations into Q4 of 2018​.  Full Article

FDA gives "orphan drug" status to Idera's skin cancer drug
Thursday, 22 Jun 2017 04:30pm EDT 

June 22 (Reuters) - Idera Pharmaceuticals Inc -:Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma.Idera Pharmaceuticals Inc - expects to complete enrollment of phase 2 multicenter trial in h2 2017, overall response rate data available in q1 of 2018.Idera Pharmaceuticals - company recently initiated a trial of imo-2125 monotherapy in refractory solid tumors, including pd-1 refractory melanoma.Idera Pharmaceuticals - enrolling second arm in phase 1/2 clinical trial in patients with pd-1 refractory melanoma to study imo-2125 and pembrolizumab.  Full Article

Idera Pharmaceuticals reports Q1 loss per share $0.10
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.10.Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Qtrly Alliance revenue $ 378,000 versus $294,000.  Full Article

Idera Pharmaceuticals reports Q4 earnings per share $0.01
Wednesday, 15 Mar 2017 04:30pm EDT 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals reports fourth quarter and year end 2016 financial results and provides corporate update . Q4 earnings per share $0.01 .Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

Idera Pharma reports positive Phase 1 data for IMO-2125
Friday, 24 Feb 2017 11:30am EST 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals presents update from ongoing phase 1 dose escalation clinical trial of Intratumoral IMO-2125 in combination with Ipilimumab in metastatic melanoma patients refractory to Anti-PD-1 treatment at the 2017 ASCO-SITC clinical Immuno-Oncology Symposium . Have achieved successful completion of all our objectives in phase 1 portion of the trial .Undertaking a parallel development pathway for IMO-2125 in combination with Pembrolizumab.  Full Article

Baker Bros. Advisors LP reports 7.2 pct stake in Idera Pharmaceuticals - SEC filing
Tuesday, 11 Oct 2016 05:33pm EDT 

Baker Bros. Advisors LP:Baker Bros. Advisors LP reports 7.2 percent stake in Idera Pharmaceuticals Inc as of Oct. 7 - sec filing.  Full Article

BRIEF-U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab

* U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA Source text for Eikon: Further company coverage: